Search

LEIDEN, the Netherlands, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p

Key updates:

First Investor R&D Day on March 14, 2016 in New York, NY

LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally

LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.